Finanzen von Cue Biopharma Inc (CUE)CUECue Biopharma Inc

Evaluating the bottom line, Cue Biopharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1113.30%, while the net margin is -1943.21%. These profitability ratios, combined with a Return on Equity (ROE) of -1603.48%, provide a clear picture of how effectively CUE converts its operational activities into shareholder value.

In the context of the broader market, CUE competes directly with industry leaders such as PEPG and MXCT. With a market capitalization of $130.75M, it holds a significant position in the sector. When comparing efficiency, CUE's gross margin of 100.00% stands against PEPG's N/A and MXCT's 63.86%. Such benchmarking helps identify whether Cue Biopharma, Inc. is trading at a premium or discount relative to its financial performance.

Cue Biopharma has shown significant revenue growth, with Q2 2026 revenue at $7.88 million, up from $2.95 million a year ago, driven by milestone payments. However, the company also reported a substantial net loss of $153.07 million in the same quarter, highlighting ongoing financial challenges.